Puma Bio (PBYI) Restricting Access to Breast Cancer Event at ASCO 2015 - TheStreet
Articles with Puma Biotechnology
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma BioEvolution: An Experimental Shoe That Adapts To The Body - Visual Atelier 8
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PumaBiotech (@pumabiotech) / Twitter
Puma Bio Stock: Still Worthy After Earnings Surprise (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Puma Bio: Now Or Never. I Go With Never (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma's BioEvolution Project Introduces A Shoe That Adapts To The Body – FashNerd
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
